RAD51 and bladder transitional cell carcinoma: Given the genetic landscape suggesting a putative ATR- and HR-deficiency in BLCA, our findings provide a strong rationale for the clinical evaluation of ATR inhibitors as radio-sensitizers, as well as for their combination with RAD51 inhibitors to exploit synthetic vulnerabilities in future therapeutic strategies.